Penumbra Inc. (PEN)
Compared to Estimates, Penumbra (PEN) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Penumbra (PEN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Penumbra (PEN) Surpasses Q4 Earnings and Revenue Estimates
Penumbra (PEN) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $0.97 per share a year ago.
Penumbra (PEN) Moves 11.8% Higher: Will This Strength Last?
Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Boston Scientific to acquire Penumbra in $14.5B deal
Boston Scientific Corp (NYSE:BSX, XETRA:BSX) announced a definitive agreement to acquire medical device company Penumbra (NYSE:PEN) in a cash and stock transaction valuing Penumbra at $374 per share, or approximately $14.5 billion in enterprise value. Penumbra shares rose almost 12% on the news to about $350, while Boston Scientific shares fell 4.5% to about $90.
Boston Scientific is buying Penumbra for $14.5 billion, gaining entry to ‘fast-growing' vascular segments
Penumbra's stock was up about 14% after the deal was announced Thursday morning.
Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock
Boston Scientific has agreed to buy thrombectomy company Penumbra for about $15 billion in cash and stock in a deal that bolsters its cardiovascular portfolio.
Boston Scientific to buy Penumbra in deal valued at $14.5 billion
Boston Scientific said on Thursday it will buy Penumbra in a deal valued at about $14.5 billion.
Penumbra, Inc. (PEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Penumbra, Inc. (PEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why Penumbra (PEN) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
PEN's expanding thrombectomy portfolio and growing international footprint support momentum, even as FX and macro pressures pose risks.
